Discovery
Preclinical
Phase 1
Phase 1b Dose Esc.

AB928 (A2aR/A2bR Antagonist) ⇓

AB928 + AB122 (anti-PD-1)
 
 
 
AB928 + Chemotherapy
 
 
 

AB680 (Small Molecule CD73i) ⇓

AB680 (IV)
 
 
Phase 1 in HVs initiated
AB680 (oral)
 
 
IND-enabling

Antibody Programs ⇓

AB122 (anti-PD-1 Antibody)
 
 
Enrolling in solid tumors
AB154 (anti-TIGIT Antibody)
 
 
Enrolling in solid tumors

Other Small Molecules ⇓

AB745 (A2aR Antagonist)
 
IND-enabling
Arginase inhibitor
 
 
Lead optimization

AB928

AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR. Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid…

read more

AB680

AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Adenosine is a powerful…

read more

AB122

AB122 is a monoclonal antibody  (mAb) that potently and selectively blocks a protein called PD-1. This immune checkpoint is expressed by tumor-infiltrating T cells that recognize tumor antigens but…

read more

AB154

AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT. Like some of the first-generation immune checkpoints (e.g., PD-1 and CTLA-4)…

read more